Literature DB >> 25556720

Epicardial fat accumulation, cardiometabolic profile and cardiovascular events in patients with stages 3-5 chronic kidney disease.

A C Cordeiro1,2, F C Amparo3, M A C Oliveira4, C Amodeo2, P Smanio4, I M F Pinto5, B Lindholm1, P Stenvinkel1, J J Carrero1.   

Abstract

BACKGROUND: It has been hypothesized that epicardial adipose tissue (EAT) exerts pathogenic effects on cardiac structures. We analysed the associations between EAT and both cardiovascular (CV) disease risk factors and CV events in patients with chronic kidney disease (CKD). PATIENTS AND METHODS: We included 277 nondialysed patients [median age 61, interquartile range (IQR) 53-68 years; 63% men] with stages 3-5 CKD in this cross-sectional evaluation. EAT and abdominal visceral adipose tissue (VAT) were assessed by computed tomography. Patients were followed for median 32 (IQR 20-39) months, and the composite of fatal and nonfatal CV events was recorded.
RESULTS: With increasing EAT quartiles, patients were older, had higher glomerular filtration rate, body mass index, waist, VAT and coronary calcification, higher levels of haemoglobin, triglycerides, albumin, C-reactive protein and leptin and higher prevalence of left ventricular hypertrophy and myocardial ischaemia; total and high-density lipoprotein cholesterol, 25-hydroxy-vitamin D and 1, 25-dihydroxy-vitamin D progressively decreased. Associations between EAT and cardiac alterations were not independent of VAT. During follow-up, 58 CV events occurred. A 1-SD higher EAT volume was associated with an increased risk of CV events in crude [hazard ratio (HR) 1.41, 95% confidence interval (CI) (1.12-1.78) and adjusted (HR 1.55, 95% CI 1.21-1.99) Cox models. However, adding EAT to a standard CV disease risk prediction model did not result in a clinically relevant improvement in prediction.
CONCLUSION: Epicardial adipose tissue accumulation in patients with CKD increases the risk of CV events independent of general adiposity. This is consistent with the notion of a local pathogenic effect of EAT on the heart or heart vessels, or both. However, EAT adds negligible explanatory power to standard CV disease risk factors.
© 2015 The Association for the Publication of the Journal of Internal Medicine.

Entities:  

Keywords:  obesity; outcomes; pericardial fat; renal disease; uraemia

Mesh:

Year:  2015        PMID: 25556720     DOI: 10.1111/joim.12344

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  15 in total

1.  Epicardial adipose tissue volume increase in hemodialysis patients treated with sevelamer or calcium-based phosphate binders: a substudy of the Renagel in new dialysis trial.

Authors:  Sung Min Ko; Chao Zhang; Zhengjia Chen; Luis D'Marco; Antonio Bellasi; Arthur E Stillman; Geoffrey Block; Paolo Raggi
Journal:  J Nephrol       Date:  2016-04-21       Impact factor: 3.902

Review 2.  Epicardial adipose tissue: new parameter for cardiovascular risk assessment in high risk populations.

Authors:  Roberta Russo; Biagio Di Iorio; Luca Di Lullo; Domenico Russo
Journal:  J Nephrol       Date:  2018-04-27       Impact factor: 3.902

Review 3.  Leptin, cardiovascular diseases and type 2 diabetes mellitus.

Authors:  Niki Katsiki; Dimitri P Mikhailidis; Maciej Banach
Journal:  Acta Pharmacol Sin       Date:  2018-06-07       Impact factor: 6.150

4.  Cardiac MRI measurements of pericardial adipose tissue volumes in patients on in-centre nocturnal hemodialysis.

Authors:  Sean Cai; Ron Wald; Djeven P Deva; Mercedeh Kiaii; Ming-Yen Ng; Gauri R Karur; Oblugbenga Bello; Zhuo Jun Li; Jonathon Leipsic; Laura Jimenez-Juan; Anish Kirpalani; Kim A Connelly; Andrew T Yan
Journal:  J Nephrol       Date:  2019-11-14       Impact factor: 3.902

5.  Epicardial fat, cardiovascular risk factors and calcifications in patients with chronic kidney disease.

Authors:  Turgay Saritas; Sebastian Daniel Reinartz; Jennifer Nadal; Jonas Schmoee; Matthias Schmid; Mohamed Marwan; Stephan Achenbach; Stefan Störk; Christoph Wanner; Kai-Uwe Eckardt; Jürgen Floege; Markus Peter Schneider; Georg Schlieper
Journal:  Clin Kidney J       Date:  2019-04-08

6.  Epicardial Fat Thickness in Patients with Autosomal Dominant Polycystic Kidney Disease.

Authors:  Antonio Concistrè; Luigi Petramala; Gianmarco Scoccia; Susanna Sciomer; Valeria Bisogni; Vincenza Saracino; Gino Iannucci; Silvia Lai; Daniela Mastroluca; Gianluca Iacobellis; Claudio Letizia
Journal:  Cardiorenal Med       Date:  2018-05-03       Impact factor: 2.041

7.  The influence of body composition on renal function in patients with coronary artery disease and its prognostic significance: a retrospective cohort study.

Authors:  Yong Peng; Hua Wang; Fei Chen; Fang-Yang Huang; Tian-Li Xia; Yan-Biao Liao; Hua Chai; Peng-Ju Wang; Zhi-Liang Zuo; Wei Liu; Chen Zhang; Yi-Jian Li; Yi-Yue Gui; Mao Chen; De-Jia Huang
Journal:  Cardiovasc Diabetol       Date:  2016-08-02       Impact factor: 9.951

8.  Is there relationship between epicardial fat and cardiovascular parameters in incident kidney transplant patients? A post-hoc analysis.

Authors:  Daniel Constantino Yazbek; Aluizio Barbosa Carvalho; Cinara Sa Barros; Jose Osmar Medina Pestana; Carlos Eduardo Rochitte; Raul Dias Dos Santos Filho; Maria Eugênia F Canziani
Journal:  PLoS One       Date:  2018-02-21       Impact factor: 3.240

9.  Relationship Between Epicardial Adipose Tissue and Body Composition as Determined by Multi-Frequency Bioelectrical Impedance Analysis in Patients with Stage 5 Chronic Kidney Disease.

Authors:  Zülfükar Yilmaz; Hasan İnce; Emre Aydin; Yasar Yildirim; Fatma Yilmaz Aydin; Enver Yüksel; Aziz Karabulut; Lezgin Dursun; Ali Kemal Kadiroğlu; Mehmet Emin Yilmaz
Journal:  Med Sci Monit       Date:  2020-02-07

Review 10.  Epicardial Adipose Tissue, Adiponectin and Leptin: A Potential Source of Cardiovascular Risk in Chronic Kidney Disease.

Authors:  Luis D'Marco; Maria Jesús Puchades; Jose Luis Gorriz; Maria Romero-Parra; Marcos Lima-Martínez; Carlos Soto; Valmore Bermúdez; Paolo Raggi
Journal:  Int J Mol Sci       Date:  2020-02-01       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.